Drugs / Samuraciclib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07645651 | Oct 2026 → Jul 2027 expected | pancreatic ductal adenocarcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07665684 | Jul 2026 → May 2029 expected | mucinous adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06125522 | Jan 2024 → Dec 2026 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05963997 | Oct 2023 → Mar 2026 | breast cancer | Carrick Therapeutics Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05963984 | Nov 2023 → Mar 2025 | breast cancer | Carrick Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samuraciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07665684 ↗ |
| Route | Oral | “360 mg orally once a day” NCT04802759 ↗ |